Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix Health plc RNS Release

Successful launch of products at Supply Side West


RNS Number : 6065S
OptiBiotix Health PLC
04 October 2017
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Successful launch of LPLDL® and SlimBiome® products at Supply Side West 2017

 

OptiBiotix  Health  p lc (AI M:OPTI), a life sciences  busi ness  d eveloping compou n ds to tackle obesity,high cholesterol, and diabetes  a nnounces the successful launch of its SlimBiome® and LPLDL® products at Supply Side West in Las Vegas, on 27-28 September 2017. The exhibition provided the opportunity to connect with 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries. The event also created the opportunity to meet with senior executives from existing corporate partners and potential new corporate partners, as well as distributors from Europe, the USA and Asia.   

 

The Company recently obtained FDA registration for both its LPLDL® and SlimBiome® product ranges allowing it to present its products at Supply Side West as the first of a number of commercial steps to supply these functional ingredients to food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market. LPLDL® was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, whilst SlimBiome® was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients.  

 

Both LPLDL® and SlimBiome® were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia and the USA. Further updates will be provided as interest develops into commercial agreements but early outcomes from the exhibition include:-

 

1. Sacco have appointed Dr Lucio Lepera as Product Manager for LPLDL®. This is a significant financial commitment from Sacco, to support entry to the US probiotic market and extend the opportunities offered by LPLDL® into dairy applications to access the $35.5 billion probiotic dairy market.

 

2. Cereal Ingredients have incorporated SlimBiome® into their range of cereal based particulates and speciality ingredients. This technical innovation extends the application of SlimBiome® into bakery products (e.g. cookies, cakes and tortillas), breakfast cereals (puffs and flakes), crackers, toppings (e.g. salad, breakfast) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars. This significantly extends the scale of the opportunity beyond weight management into the nutraceutical, health and wellbeing industry sectors.

 

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. We are particularly pleased by the commitment shown by our partners who have invested significant financial resources in providing exhibition space, appointed and trained new personnel, and developed new products at their own cost, to support the commercialisation of our products. We believe this reflects the high level of confidence in the commercial potential of our products. As we build the range of applications and geographic scope of LPLDL® and SlimBiome® with new manufacturing and distribution partners; the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

 

 

 

 

 

For further information, please contact:

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Walbrook PR Ltd

Tel:020 7933 8780 or  [email protected]

Anna Dunphy

Mob: 07876 741 001

 

 

About OptiBiotix - www.optibiotix.com  

 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABUBDGIXGBGRX



OptiBiotix Health plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use